ViroCell
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
Leveraging the team’s 20-year track record of manufacturing more than 100 unique vectors, ViroCell is helping to accelerate the development of crucial, cutting edge therapies so that disease can recede and progress can prevail.
ViroCell is working in partnership with the Royal Free Hospital and Great Ormond Street Hospital.
Website: www.virocell.com
02/11/2023
Global Interconnection Group (GIG) is delighted to have signed an exclusivity agreement with a major UK energy company to explore collaboration on the Atlantic SuperConnection interconnection project.
Click the link in the title to read more
02/11/2023
Pension SuperFund Capital, which oversees UK commercial pension consolidator Pension SuperFund, has reached an agreement to acquire the parent group of Options Pensions, STM Group, for £35.6m.
The purchase was made through the Pension SuperFund Capital acquisition arm Bidco. It is expected that if the full value is delivered by the deferred consideration units (DCU), the acquisition value could rise to £39.8m, it was announced this morning.
The scheme shareholders will also be entitled to receive 60 pence per share in cash, rising to 67 pence per share if full value is delivered by DCU.
We’re glad to see that you may be inspiring others with our journalistic content. We ask that you copy our content for personal use only, so as not to violate our Terms and Conditions. Otherwise, ask about our group memberships via lorenzo.passarella@ipe.com. Text copied from: https://www.ipe.com/news/pension-superfund-capital-acquires-stm-group-for-356m/10069392.article
02/11/2023
ViroCell’s manufacturing operations are housed within Great Ormond Street Hospital’s state-of-the-art GMP accredited unit for manufacturing cell and gene therapies, the Zayed Centre for Research
London, UK and New York, US, 1 November 2023 – ViroCell Biologics (“ViroCell” or the “Company”), a specialist contract development and manufacturing organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces that the Company is now able to manufacture and globally export viral vectors from Great Ormond Street Hospital’s (GOSH) state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials. This follows the grant of a Manufacturer’s Authorisation License (MIA) to GOSH to manufacture viral vectors by the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA).
Read more by clicking the title link
02/06/2023
An experienced team of Private Markets analytics specialists supporting the industry renowned work of Professor Oliver Gottschalg of HEC Paris is delighted to announce the launch of Gottschalg Analytics as an independent second-generation provider of performance intelligence services for the Private Markets.
30/03/2023
Pension Insurance Corporation Group Limited1 ('PICG' or the 'Company'), ultimate parent company of Pension Insurance Corporation plc ('PIC'), the specialist insurer of UK defined benefit pension schemes, today announces its final results for the 12 months to 31 December 2022.
13/03/2023
DCAC announced proposals to form the Advanced Cables Business Combination in the press release issued by the Company on 20th February 2023. The DCAC Board has now decided to expedite the proposals, and DCAC has therefore agreed an exclusive option to acquire the holding company of Advanced Cables, Global InterConnection Group SA (“GIG” or the “Target”). Besides Advanced Cables, GIG is also the holding company of ASC Energy Limited. It is intended that DCAC will be renamed "Global InterConnection Group Limited" on completion of the Business Combination.